Claims for Patent: 6,420,119

Summary for Patent: 6,420,119

Title:	Methods of diagnosing and treating urinary incontinence relating to collagen proteolysis in pelvic supporting tissue
Abstract:	Methods are disclosed for diagnosing urinary incontinence or a predisposition to urinary incontinence in a subject by determining the ratio of expression levels of MMPs/TIMPs in pelvic supporting tissue of the subject and comparing the ratio to a predetermined indicator. A diagnostic kit is also disclosed. Methods are disclosed for treating urinary incontinence by reducing proteolysis of collagen in pelvic supporting tissue of the subject and for identifying therapeutic agents in in vitro screens.
Inventor(s):	Polan; Mary Lake (Palo Alto, CA), Chen; Bertha (Menlo Park, CA)
Assignee:	The Board of Trustees of the Leland Stanford Jr. University (Palo Alto, CA)
Application Number:	09/689,291
Patent Claims:	1. A method for diagnosing urinary incontinence or predisposition to urinary incontinence in a subject comprising assessing the degree of proteolysis of collagen in pelvic supporting tissue of the subject. 2. The method of claim 1, wherein the degree of proteolysis is assessed by determining one or more MMP mRNA levels in pelvic supporting tissue of the subject; determining one or more TIMP mRNA levels in pelvic supporting tissue in the subject; calculating a ratio of MMP/TIMP mRNA levels; and comparing the ratio to a predetermined indicator of normal and abnormal values for the ratio. 3. The method of claim 2, wherein the ratio is based on determinations of MMP-1 and TIMP-1 levels in pelvic supporting tissue in the subject. 4. The method of claim 2, wherein the pelvic supporting tissue is selected from the group consisting of: vaginal cuff tissue; periurethral tissue; periuterine tissue; vaginal epithelium; and cultured cells from pelvic supporting tissue. 5. The method of claim 2, wherein the predetermined indicator is an empirically determined value. 6. The method of claim 2, wherein the predetermined indicator is a previously measured value of MMP/TIMP level in the subject. 7. The method of claim 2, further including determining collagenase activity in pelvic supporting tissue in the subject and comparing the activity to a predetermined indicator. 8. A kit for use with the method of claim 2, comprising a test for the level of one or more MMPs in a tissue sample, a test for the level of one or more TIMPs in a tissue sample, and a predetermined indicator of normal and abnormal values for the MMP/TIMP ratio. 9. A method for treating a patient diagnosed as having urinary incontinence or predisposition to urinary incontinence according to the method of claim 2, comprising reducing proteolysis of collagen in pelvic supporting tissue of the patient and determining the effect of the treatment on the patient's condition. 10. The method of claim 9, wherein reducing proteolysis of collagen in pelvic supporting tissue is accomplished by administering to the patient an effective amount of one or more of the following: (a) an MMP inhibitor; (b) a TIMP or a TIMP analog or derivative; (c) a modulator of MMP levels; and (d) a modulator of TIMP levels. 11. The method of claim 2, wherein the ratio is based on determinations of mRNA levels of one or more MMPs selected from the group consisting of MMP-1, MMP-2 and MMP-9 and one or more TIMPs selected from the group consisting of TIMP-1, TIMP-2 and TIMP-3. 12. The method of claim 1, wherein the degree of proteolysis is assessed by measuring collagenase activity in pelvic supporting tissue in the subject and comparing the activity to a predetermined indicator of normal and abnormal values.

Details for Patent 6,420,119

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2019-10-12